Business Context and Reporting Period
Cytosorbents Corp filed a Form 8-K Current Report on September 30, 2013, regarding a material definitive agreement entered into on that date. The company is incorporated in Nevada and headquartered in Monmouth Junction, New Jersey.
Key Financial Metrics and Transaction Details
- Capital Raised: The company issued convertible notes with an aggregate principal amount of $745,000, consisting of a $500,000 base offering plus a $245,000 oversubscription.
- Interest Rate: The notes bear interest at an annual rate of 8%.
- Maturity: The notes mature one year from the closing date (September 30, 2014).
- Conversion Terms: Notes automatically convert into common stock at a price of $0.10 per share at maturity or earlier at the purchaser's option. Full conversion would result in the issuance of 7,450,000 shares.
- Warrants: Warrants were issued with 50% coverage, exercisable at $0.125 per share.
- Transaction Costs: Investment agent fees incurred were $16,450.
- Repayment Obligation: The company is not required to repay the notes in cash; repayment is via conversion to equity.
Material Changes
This filing represents a new direct financial obligation and an unregistered sale of equity securities. The transaction increases the company's debt load temporarily until conversion, with a potential dilution of 7,450,000 shares upon full conversion. No prior comparable period data is provided in this specific filing as it reports a discrete event rather than periodic financial results.
Guidance, Risks, and Contingencies
- Regulatory Exemption: The securities were issued under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D, relying on the fact that investors were accredited and the offering was not public.
- Dilution Risk: The notes do not contain anti-dilution provisions.
- Liquidity: There are no registration rights on the common stock underlying the notes or warrants, which may affect the liquidity of the shares upon conversion.
- Management Commentary: The filing contains no forward-looking guidance or management commentary beyond the terms of the agreement.
Investor Verification Checklist
- Verify the total number of shares outstanding post-conversion to assess dilution impact.
- Confirm the company's cash position to ensure it can service the 8% interest until conversion.
- Review the specific terms in Exhibits 4.1 (Form of Convertible Note) and 4.2 (Form of Warrant) for any covenants not summarized in the text.
- Check subsequent filings for any early conversion events or default notices.